Search Within

Heiko Schoder

  1. "Solid Tumor Oncology Division"
Formats
  1. Meeting Abstract (68)
  2. Journal Article (61)
  3. Book Section (1)
  4. Editorial (1)
  5. Review (1)
Groups
  1. Department of Medicine (132)
  2. Molecular Imaging and Therapy Service (132)
  3. Radiology, Department of (132)
  4. Solid Tumor Oncology Division (132)
  5. Survivorship Research (61)
  6. Epidemiology and Biostatistics (60)

More Groups

People
  1. John Humm (38)
  2. Nancy Lee (32)
  3. Steven Larson (32)
  4. Eric Sherman (30)
  5. Howard Scher (25)
  6. Michael Morris (25)

More People

Years
  1. 2025 (3)
  2. 2024 (17)
  3. 2023 (11)
  4. 2022 (9)
  5. 2021 (11)
  6. 2020 (5)

More Years

Publications
  1. Journal of Clinical Oncology (39)
  2. International Journal of Radiation Oncology, Biology, Physics (17)
  3. Journal of Nuclear Medicine (15)
  4. Blood (8)
  5. Clinical Cancer Research (4)
  6. European Journal of Nuclear Medicine and Molecular Imaging (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (39)
  2. Elsevier Inc. (22)
  3. Society of Nuclear Medicine (15)
  4. Springer (13)
  5. American Society of Hematology (8)
  6. American Association for Cancer Research (7)

More Publishers

Results (132)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Interim analysis of a prospective validation of 2 blood-based genomic assessments (PPQ and NETest) to determine the clinical efficacy of (177)Lu-DOTATATE in neuroendocrine tumors
    Journal Article

    Bodei, L.; Raj, N.; Do, R. K.; Mauguen, A.; Krebs, S.; Reidy-Lagunes, D.; Schöder, H.
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • Advances in prostate cancer imaging
    Book Section

    Razmaria, A. A.; Schoder, H.; Morris, M. J.
    In Stratton, K. L.; Morgans, A. K. (Eds.) Urologic Oncology: Multidisciplinary Care for Patients (2022)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: Extended follow-up with evaluation of baseline metabolic tumor volume and PET2
    Meeting Abstract

    Stuver, R.; Michaud, L.; Casulo, C.; Advani, R. H.; Budde, E. L.; Barr, P. M.; Batlevi, C. L.; Caron, P. C.; Constine, L. S.; Dandapani, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Treatment response and clinical outcomes of well-differentiated high-grade neuroendocrine tumors to lutetium-177-DOTATATE
    Journal Article

    Raj, N.; Coffman, K.; Le, T.; Do, R. K. G.; Rafailov, J.; Choi, Y.; Chou, J. F.; Capanu, M.; Dunphy, M.; Fox, J. J.; more...
    Neuroendocrinology (2022)

    Fulltext@MSK | Save
  • Intra-treatment tumor apparent diffusion coefficient, a quantitative imaging metric, is associated with neck nodal recurrence in de-escalated treatment of HPV-positive oropharyngeal cancer (OPC)
    Meeting Abstract

    Diplas, B.; Han, J.; Paudyal, R.; Oh, J. H.; Sherman, E.; Schoder, H.; Hatzoglou, V.; Yu, Y.; Wong, R. J.; Wray, R.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • Development and validation of diagnostic interpretation criteria for evaluation of F-18 Fluoromisonidazole hypoxia PET/CT – Inter-reader reliability and accuracy
    Meeting Abstract

    Wray, R.; Mauguen, A.; Michaud, L.; Leithner, D.; Sherman, E.; Riaz, N.; Humm, J.; Mirtcheva, R.; Boyle, J. O.; Wong, R. J.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • Tumor volume predicts for baseline hypoxia status in HPV related oropharyngeal carcinomas (OPC) that underwent major radiation de-escalation: The 30 Reduction in Oropharyngeal Cancer Trial
    Meeting Abstract

    Han, J.; Diplas, B.; Paudyal, R.; Oh, J. H.; Sherman, E.; Schoder, H.; Hatzoglou, V.; Yu, Y.; Wong, R. J.; Wray, R.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • Treatment response and clinical outcomes of well-differentiated (WD) high-grade (HG) neuroendocrine tumors (NETs) to (177)Lu-DOTATATE
    Meeting Abstract

    Coffman, K.; Bodei, L.; Le, T.; Choi, Y.; Chou, J.; Capanu, M.; Dunphy, M.; Fox, J.; Grewal, R.; Reddy, R.; more...
    Pancreas (2022)

    Fulltext@MSK | Save
  • Blood-based genomic assessment of clinical efficacy and toxicity of (177)Lu-DOTATATE of neuroendocrine tumors
    Meeting Abstract

    Bodei, L.; Raj, N.; Do, K. G.; Krebs, S.; Reidy-Lagunes, D.; Kidd, M.; Drozdov, I.; Modlin, I.; Schöder, H.
    Pancreas (2022)

    Fulltext@MSK | Save
  • Phase I/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring
    Journal Article

    Stewart, C. M.; Michaud, L.; Whiting, K.; Nakajima, R.; Nichols, C.; De Frank, S.; Hamlin, P. A. Jr; Matasar, M. J.; Gerecitano, J. F.; Drullinsky, P.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save